Efficacy and safety of once-weekly semaglutide 20 mg versus 10 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
The content provided in this blog is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment
After about 46 half-lives, the circulating drug level becomes very low, meaning most of the parent peptide has been cleared from systemic circulation
With the accumulation of related studies, current evidence has been concentrated mainly in diseases that have been more extensively investigated, such as SLE, RA, IBD, and MS
Compared with published studies of standard care after GLP-1 discontinuation, Noom members had roughly 3x stronger weight maintenance
More Products from Titan Biotech Ltd